Levosimendan for patients with impaired left ventricular function undergoing cardiac surgery

Interactive Cardiovascular and Thoracic Surgery

Volumn 5, Issue 3, 2006, Pages 322-326

  Tokuda, Yoshiyuki ^a   Grant, Peter W ^a   Wolfenden, Hugh D ^a   Manganas, Con ^a   Lyon, William J ^a   Murala, John S K ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Impaired ventricular function; Levosimendan; Postoperative care

Indexed keywords

ADRENALIN; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; NORADRENALIN;

ADULT; AGED; AORTA BALLOON; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FORWARD HEART FAILURE; HEART ASSIST DEVICE; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE FAILURE; HEART SURGERY; HUMAN; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SYSTEMIC VASCULAR RESISTANCE;

EID: 33744472781     PISSN: 15699293     EISSN: 15699293     Source Type: Journal    
DOI: 10.1510/icvts.2005.122390     Document Type: Review

References (11)

1. Packer M. The search for the ideal positive inotropic agent. N Engl J Med 1993;329:201-202.
2. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during levosimendan infusion in congestive heart failure. J Clin Pharmacol Ther 2000;68:522-531.
3. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometrictension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-2147.
4. + channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-259.
5. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
6. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, Hutchins S, Leier CV, LeJemtel TH, Loh E, Nicklas J, Ogilby D, Singh BN, Smith W. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-2227.
7. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-228.
8. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, Verkkala K, Mattila S, Salmenpera M. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-668.
9. Nashef SAM, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R, the EuroSCORE study group. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999;16:9-13.
10. Haikala H, Nissinen E, Etemadzadeh E, levijoki J, Linden I-B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995;25:794-801.
11. Singh BN, Lilleberg J, Sandell EP, Ylönen V, Lehtonen L, Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 1999;83:16-20.